

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110

Status RECRUITING
Sponsor AbbVie
Enrollment 700 participants

Key Eligibility Criteria

Inclusion (3)

- Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
- Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
- Decision to treat with risankizumab is made prior to and independently of study participation.

Exclusion (3)

- History of a sleep disorder diagnosis which the patient is currently being treated for.
- Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
- Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Locations (60 total)

Rejuvenation Dermatology - Edmonton Downtown /ID# 276688, Edmonton, Alberta, Canada
Winnipeg Clinic /ID# 276751, Winnipeg, Manitoba, Canada
Wiseman Dermatology Research /ID# 276847, Winnipeg, Manitoba, Canada
... and 57 more locations